PT-141 Dosage in the Research and the Label

Before the details

In plain English: this page reports PT-141 dosage the way the official label and the trials state it — as a finding, never as instructions to follow. The approved drug, bremelanotide, is given as a single 1.75 mg shot just under the skin (subcutaneous — injected into the fat layer beneath the skin), used only when needed, and not more than once a day or eight times a month ^[6]. It leaves the bloodstream within hours. The approved finished product is a ready-to-use injection, not a powder you mix. None of the numbers below are a protocol for a reader; they are the published record.

PT-141 Dosage in the Research

The approved label for the HSDD indication specifies 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than 8 doses per month ^[6]. Phase 2 dose-finding in women studied 0.75 mg, 1.25 mg, and 1.75 mg before the 1.75 mg dose was carried into the pivotal trials ^[3].

Other research routes used different ranges entirely. Early intranasal development in men with erectile dysfunction escalated into the ~7-20 mg range, with a statistically significant erectile response above roughly 7 mg ^[1]. A Phase 1 metabolic study administered subcutaneous doses up to 2.5 mg, up to three times daily for 15 days, strictly as a research protocol ^[6]. These are reported here as study facts; they are not a guide for use.

PT-141 Dosage for Women in the Trials

For the approved HSDD indication in premenopausal women, the label dose was 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, with the same one-dose-per-24-hours and eight-doses-per-month ceilings ^[6]. That regimen is exactly what the two RECONNECT Phase 3 trials administered to the 1,267 women studied ^[3], and what the 52-week open-label extension carried forward ^[4]. Reported as a label and trial finding — this site recommends no dose for any person.

Route of Administration

The approved route is subcutaneous injection — a shot into the fat layer just under the skin — self-administered at least 45 minutes before anticipated activity per the label ^[6]. The approved finished drug is a ready-to-use, single-dose injection, not a reconstituted powder; "PT-141 research chemical" material is a laboratory reagent and is not the approved product, so no human-use or mixing instructions are given here ^[6]. An earlier intranasal formulation was tested in development but discontinued because of pharmacokinetic variability ^[6].

How Long PT-141 Lasts

After subcutaneous injection, bremelanotide reaches peak blood levels fast — median Tmax around 0.5-1.0 hours — and clears with a terminal half-life of approximately 2.7 hours (range 1.9-4.0 hours) per the US prescribing information ^[6]. So in the bloodstream it is a short-acting molecule.

The felt duration is a separate question from the blood level. The mechanistic fMRI study reported increased sexual desire for up to 24 hours after dosing ^[5] — a reminder that a centrally acting drug's effect on a brain circuit need not track its plasma concentration minute for minute. Both facts are true and both belong on the page.

PT-141 Half-Life

The PT-141 half-life is approximately 2.7 hours (range 1.9-4.0 h) by the subcutaneous route, per the FDA label ^[6]. Early intranasal studies reported shorter terminal half-lives of 1.85-2.09 hours ^[6]. Supporting pharmacokinetics: a volume of distribution of ~25.0 L, clearance of ~6.5 L/hr, roughly 21% serum protein binding, metabolism by hydrolysis of the cyclic-peptide bonds and peptidase digestion, and excretion split 64.8% renal and 22.8% fecal in a radiolabeled study ^[6].

Field Reports (Not Clinical Data)

The following are unverified community reports, not evidence and not advice. They are paraphrased from commonly described first-hand accounts and the question patterns people raise online — included for transparency, not as findings. Nothing here is attributed to a journal, and none of it should be read as a protocol.

Researchers handling "PT-141 research chemical" material commonly discuss reconstitution because, unlike the ready-to-use approved injection, lab reagent is a powder; community accounts frequently describe a rapid-onset warm "flush" within roughly the first hour, nausea arriving early and sometimes settling with experience, and a spontaneous, brain-led sense of arousal rather than a purely physical effect. Many community posts also repeatedly pass around a caution about transient skin or facial darkening with frequent repeat dosing. These are reported experiences only — the cited pharmacokinetics above (PT-141 half-life) and the documented adverse-event profile on the PT-141 side effects page are the actual evidence.